title: Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Chan Y
authors.identifier: 0000-0001-7988-1565
authors.initials: CY
authors.lastname: Cheah
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Loretta J
authors.initials: LJ
authors.lastname: Nastoupil
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Fanale
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Frederick B
authors.initials: FB
authors.lastname: Hagemeister
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. nfowler@mdanderson.org.
authors.forename: Nathan H
authors.initials: NH
authors.lastname: Fowler
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D003141:Communicable Diseases / Q000209:etiology*; D006402:Hematologic Diseases / Q000209:etiology*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000069283:Rituximab / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000069283:Rituximab; D000069461:Bendamustine Hydrochloride; D008942:Mitoxantrone
keywords: bendamustine; chemoimmunotherapy; follicular lymphoma; mitoxantrone; rituximab